Stock Events

Stock Events

Acumen Pharmaceuticals 

$2.38
0
+$0.05+2.15% Today

Statistics

Day High
2.43
Day Low
2.36
52W High
-
52W Low
-
Volume
1,151
Avg. Volume
-
Mkt Cap
144.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.6
-0.53
-0.45
-0.37
Expected EPS
-0.373467
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-204.66MNet Income

Analyst Ratings

$8.00Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABOS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a leading biotech company in Alzheimer's disease research, directly competing with Acumen's focus on Alzheimer's therapeutics.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has advanced Alzheimer's disease treatments in its pipeline, making it a direct competitor to Acumen in the Alzheimer's space.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences focuses on developing novel therapeutics for neurodegenerative diseases like Alzheimer's, positioning it as a competitor.
Prothena
PRTA
Mkt Cap578.67M
Prothena Corporation is engaged in the development of treatments for neurodegenerative diseases, including Alzheimer's, competing with Acumen's objectives.
Athira Pharma Inc
ATHA
Mkt Cap16.39M
Athira Pharma focuses on regenerating brain function, directly competing in the Alzheimer's treatment space with Acumen.
Cass Information Systems
CASS
Mkt Cap516.78M
Cassava Sciences is working on the treatment of Alzheimer's disease, making it a competitor to Acumen in Alzheimer's research and development.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, with its focus on RNA interference (RNAi) therapeutics, could potentially enter Alzheimer's or related markets, posing indirect competition.
Curis
CRIS
Mkt Cap18.62M
Curis, Inc. is involved in developing cancer treatments but its research into novel drug developments could pivot towards neurodegenerative diseases, offering indirect competition.

About

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Show more...
CEO
ISIN
US00509G2093

Listings

XNAS
US
ABOS
BOATS
BOATS
ABOS.BOATS

0 Comments

Share your thoughts

FAQ

What is Acumen Pharmaceuticals stock price today?▼
The current price of ABOS.BOATS is $2.38 USD — it has increased by +2.15% in the past 24 hours. Watch Acumen Pharmaceuticals stock price performance more closely on the chart.
What is Acumen Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acumen Pharmaceuticals stocks are traded under the ticker ABOS.BOATS.
What is Acumen Pharmaceuticals market cap?▼
Today Acumen Pharmaceuticals has the market capitalization of 144.16M
When is the next Acumen Pharmaceuticals earnings date?▼
Acumen Pharmaceuticals is going to release the next earnings report on May 19, 2026.
What were Acumen Pharmaceuticals earnings last quarter?▼
ABOS.BOATS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.45 USD resulting in a +11.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Acumen Pharmaceuticals revenue for the last year?▼
Acumen Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Acumen Pharmaceuticals net income for the last year?▼
ABOS.BOATS net income for the last year is -204.66M USD.
When did Acumen Pharmaceuticals complete a stock split?▼
Acumen Pharmaceuticals has not had any recent stock splits.